Payment overview · 2025
General Payments
$2,458.87
135 reported records · 25 companies
Healthcare provider profile · identity verified
Ewa Czyzewski, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LINDEN, NJ · NPI 1467473173
Verified facts
What the public records show
CMS Open Payments records show Ewa Czyzewski, MD received $2,458.87 in general payments during 2025 across 135 reported records.
AstraZeneca Pharmaceuticals LP accounted for 16.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Shingrix, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lokelma by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $414.13 | 16.8% | 21 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $378.31 | 15.4% | 21 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $208.76 | 8.5% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $151.60 | 6.2% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $128.12 | 5.2% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $122.21 | 5.0% | 9 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $117.92 | 4.8% | 7 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $106.05 | 4.3% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $96.29 | 3.9% | 6 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $91.17 | 3.7% | 3 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $85.00 | 3.5% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $79.75 | 3.2% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $74.54 | 3.0% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $71.50 | 2.9% | 4 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $55.45 | 2.3% | 2 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $54.93 | 2.2% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $38.24 | 1.6% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $36.61 | 1.5% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.11 | 1.4% | 2 | 2025 |
| MEDICOMP INC | Unresolved — no canonical attribution shown | $28.66 | 1.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $19.17 | 0.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.55 | 0.8% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $16.24 | 0.7% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.04 | 0.7% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $15.52 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,458.87 | 135 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $250.53 | 15 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $247.22 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $211.65 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $176.40 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $164.50 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $137.62 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $137.10 | 9 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $127.78 | 6 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $118.92 | 7 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $117.92 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $109.53 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $109.53 | 7 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $106.05 | 6 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $91.17 | 3 | 2025 |
Source payment records
|
|||||
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $85.00 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $80.88 | 6 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $74.54 | 3 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $71.50 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $64.93 | 5 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $54.93 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $49.05 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $43.11 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $43.11 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $43.11 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $38.24 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.64 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $36.64 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $36.61 | 2 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $34.11 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $32.36 | 2 | 2025 |
Source payment records
|
|||||
| TELEPATCH CARDIAC MONITOR Normalized: telepatch cardiac monitor |
Device | MEDICOMP INC | $28.66 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| MYALEPT Normalized: myalept |
Drug | Chiesi USA, Inc. | $15.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 161 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 69 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 152 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 29 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
161 | 54 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
69 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
29 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
57 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
69 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
152 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
97 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 780 | 275 |
| Amlodipine Besylate | Amlodipine Besylate | 678 | 262 |
| Metoprolol Succinate | Metoprolol Succinate | 480 | 165 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 458 | 181 |
| Losartan Potassium | Losartan Potassium | 442 | 149 |
| Levothyroxine Sodium | Levothyroxine Sodium | 311 | 106 |
| Metformin Hcl | Metformin Hcl | 284 | 104 |
| Simvastatin | Simvastatin | 256 | 84 |
| Carvedilol | Carvedilol | 239 | 86 |
| Furosemide | Furosemide | 212 | 82 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 203 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 201 | 72 |
| Gabapentin | Gabapentin | 186 | 95 |
| Meloxicam | Meloxicam | 167 | 102 |
| Cefuroxime | Cefuroxime Axetil | 163 | 136 |
| Farxiga | Dapagliflozin Propanediol | 161 | 54 |
| Lisinopril | Lisinopril | 158 | 53 |
| Omeprazole | Omeprazole | 152 | 59 |
| Ozempic | Semaglutide | 152 | 36 |
| Alprazolam | Alprazolam | 146 | 66 |
| Fluticasone Propionate | Fluticasone Propionate | 139 | 88 |
| Pantoprazole Sodium | Pantoprazole Sodium | 136 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 136 | 57 |
| Allopurinol | Allopurinol | 129 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 128 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 127 | 47 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 120 | 44 |
| Metformin Hcl Er | Metformin Hcl | 119 | 43 |
| Pioglitazone Hcl | Pioglitazone Hcl | 110 | 43 |
| Sertraline Hcl | Sertraline Hcl | 106 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 61 |
| Famotidine | Famotidine | 100 | 43 |
| Eliquis | Apixaban | 97 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 93 | 34 |
| Montelukast Sodium | Montelukast Sodium | 89 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 49 |
| Glimepiride | Glimepiride | 84 | 32 |
| Valsartan | Valsartan | 80 | 28 |
| Azithromycin | Azithromycin | 79 | 68 |
| Clonazepam | Clonazepam | 75 | 30 |
| Ezetimibe | Ezetimibe | 74 | 36 |
| Levofloxacin | Levofloxacin | 74 | 59 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 31 |
| Januvia | Sitagliptin Phosphate | 70 | 21 |
| Jardiance | Empagliflozin | 69 | 24 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 64 | 19 |
| Prednisone | Prednisone | 61 | 52 |
| Tramadol Hcl | Tramadol Hcl | 58 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 54 | 15 |
| Potassium Chloride | Potassium Chloride | 52 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 48 |
| Clobetasol Propionate | Clobetasol Propionate | 48 | 37 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 47 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 47 | 24 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 46 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 26 |
| Telmisartan | Telmisartan | 46 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | 16 |
| Alendronate Sodium | Alendronate Sodium | 41 | 19 |
| Trazodone Hcl | Trazodone Hcl | 40 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 39 | 30 |
| Enalapril Maleate | Enalapril Maleate | 39 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 39 | 13 |
| Spironolactone | Spironolactone | 38 | 16 |
| Ramipril | Ramipril | 37 | 12 |
| Dexamethasone | Dexamethasone | 36 | 33 |
| Clonidine Hcl | Clonidine Hcl | 35 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 35 | suppressed |
| Ketoconazole | Ketoconazole | 35 | 20 |
| Fenofibrate | Fenofibrate | 34 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | 11 |
| Xarelto | Rivaroxaban | 32 | 13 |
| Mupirocin | Mupirocin | 31 | 24 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 26 |
| Bupropion Xl | Bupropion Hcl | 29 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 24 |
| Methimazole | Methimazole | 29 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 29 | 22 |
| Benazepril Hcl | Benazepril Hcl | 28 | 12 |
| Cephalexin | Cephalexin | 28 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Kerendia | Finerenone | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 25 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 16 |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 22 | suppressed |
| Naproxen | Naproxen | 22 | 16 |
| Hydrocortisone | Hydrocortisone | 21 | 13 |
| Atenolol | Atenolol | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 17 |
| Solifenacin Succinate | Solifenacin Succinate | 20 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 16 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 15 |
| Jentadueto | Linagliptin/Metformin Hcl | 17 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 16 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Levoxyl | Levothyroxine Sodium | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Torsemide | Torsemide | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Minoxidil | Minoxidil | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 13 |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,458.87 · 135 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, BREZTRI, COMIRNATY, FARXIGA, HORIZANT, JARDIANCE, JYNARQUE, KRYSTEXXA, Korlym, MOUNJARO, MYALEPT, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, QUTENZA, RECORLEV, REPATHA, Rybelsus, SHINGRIX, SYNTHROID, TELEPATCH CARDIAC MONITOR, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, UNITHROID, Veltassa, Veozah, Wegovy, Yorvipath, ZAVZPRET, ZEPBOUND, t:slim X2 Insulin Pump with Control-IQ | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error